ScreenPoint Medical Raises €13.6M To Boost AI Breast Cancer Detection

The company has also secured €1.7 million in non-dilutive research grants. With this combined funding, ScreenPoint Medical plans to drive product innovation expand into international markets and strengthen its position in advancing the future of breast cancer diagnosis and care.

ScreenPoint Medical was founded in 2014 by Professors Nico Karssemeijer and Sir Michael Brady as a spin-off from Radboud University Medical Centre in Nijmegen, Netherlands.

The company develops AI-based technology for breast imaging to improve early breast cancer detection, reduce uncertainty, and support more personalised and precise care.

Its main product, Transpara, is an AI software suite that helps radiologists analyse 2D and 3D mammograms. It is designed to improve detection accuracy and make screening workflows more efficient.

Read Also - Planetary Raises Nearly €23M To Scale Bioeconomy Fermentation Technology

Transpara is used in over 30 countries and has processed more than 12 million mammograms. Studies show it can improve cancer detection rates while reducing radiologists’ workload.

The technology has also been validated in major clinical research, including the MASAI randomised controlled trial published in The Lancet, which reported better outcomes than standard double reading.

“This investment endorses our strategy and our shared success. We are well-positioned to scale globally and accelerate the development of solutions that make care personal and powerful. Our goal is to support clinicians and women across the full continuum of breast cancer care,” said Pieter Kroese, CEO of ScreenPoint Medical.

“ScreenPoint Medical continues to lead and innovate in applying AI to breast imaging. The opportunity to create a greater level of personalised care is vast and clinically impactful at both a patient and population level. We are excited to support ScreenPoint Medical as it builds an integrated and comprehensive approach,” said Dr Robert Epstein, MD, FACR, Health Care Senior Advisor at Insight Partners.

About ScreenPoint Medical

ScreenPoint Medical, founded in 2014, is a Breast AI company leading innovation in early breast cancer detection. Its AI-powered technology helps radiologists analyse medical images with greater precision, improve risk assessment and support personalised care pathways for better patient outcomes.